Document Preview Unavailable
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library